EUVIMEDEUVIMED entdecken
Crossref

Multiyear Recurrent Pericarditis Disease Duration: Clinical Outcomes After Cessation of Long‐Term Interleukin‐1 Pathway Inhibition Provide Insights for Chronic Management

Lucia Trotta iD, Massimo Imazio iD, Emanuele Bizzi iD, Massimo Pancrazi, Alessandro Andreis iD, Antonella Insalaco iD, Sheldon Wang, JoAnn Clair iD, Allan L Klein iD, Enrico Tombetti iD, Antonio Brucato iD, John F Paolini iD und 1 weitere

Journal of the American Heart Association · 2026

DOI: 10.1161/jaha.125.044021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Lucia Trotta und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine Ospedale Fatebenefratelli Milan Italy. Hauptthemen laut MEDLINE: Pericarditis, Recombinant Fusion Proteins, Interleukin-1, Interleukin-1beta. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recurrent pericarditis is an interleukin‐1–mediated chronic autoinflammatory disease. The phase 3 study RHAPSODY (Rilonacept Inhibition of IL‐1 Alpha and IL‐1 Beta for Recurrent Pericarditis: a Pivotal Symptomatology and Outcomes Study; NCT03737110) and long‐term extension demonstrated that rilonacept reduced the risk of recurrence. After 3 years of rilonacept treatment in RHAPSODY, Italian patients returned to standard management, as rilonacept was not commercially available.

Methods

Clinical records from Italian RHAPSODY patients were retrospectively reviewed for the 18‐month period post–long‐term extension completion to assess recurrent pericarditis disease persistence and time to recurrence after rilonacept cessation/washout. The primary outcome was pericarditis recurrence (ie, pericarditis pain plus C‐reactive protein elevation). Safety was also assessed.

Results

Seventeen patients were included in this analysis. The median disease duration (from incident episode to long‐term extension completion) was 48 (interquartile range, 41–56) months; the median duration of continuous rilonacept treatment was 28 (interquartile range, 27–30) months. Fourteen (82%) of 17 patients experienced a post‐trial off‐treatment recurrence; the remaining patients (n=3) had no pericarditis recurrences and remained offtreatment. The median time to recurrence (n=14) was 8.0 (interquartile range, 6.0–9.0 weeks). Most patients’ (n=8) post‐trial off‐treatment recurrences were managed with interleukin‐1 pathway inhibition. Some (n=4) were managed with glucocorticoids, and few (n=2) were managed with NSAIDs/colchicine. No serious adverse events were experienced.

Conclusions

The vast majority (86%) of the patients who experienced an off‐treatment recurrence after 28 months of rilonacept restarted interleukin‐1 pathway inhibition or corticosteroids, suggesting that NSAIDs/colchicine are insufficient in the management of patients with prolonged advanced disease. Rilonacept cessation and subsequent passive gradual washout is an evidence‐based pragmatic approach to determine if continued therapy is warranted to prevent subsequent recurrences.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PericarditisRecombinant Fusion ProteinsInterleukin-1Interleukin-1betaInterleukin-1alphaHumansFemaleMaleRecurrenceRetrospective StudiesTime FactorsTreatment OutcomeMiddle AgedAdultItalyTreatment Interruption

Stichwörter der Autor:innen

autoinflammatory diseaseinterleukin‐1recurrent pericarditisrilonacept

Substanzen

rilonaceptRecombinant Fusion ProteinsInterleukin-1Interleukin-1betaInterleukin-1alpha

Autor:innen und Institutionen

  • Department of Internal Medicine Ospedale Fatebenefratelli Milan Italy.
  • Department of Medicine University of Udine and Cardiothoracic Department, University Hospital Santa Maria della Misericordia Udine Italy.
  • Advanced Cardiovascular Echocardiography Unit, Cardiovascular and Thoracic Department Città della Salute e della Scienza di Torino University Hospital Turin Italy.
  • Division of Cardiology, Città della Salute e della Scienza di Torino University Hospital, Department of Medical Sciences University of Torino Turin Italy.
  • Division of of Rheumatology Ospedale Pediatrico Bambino Gesù IRCCS [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center] Rome Italy.
  • Kiniksa Pharmaceuticals Lexington MA USA.

ORCID-Profile: Lucia Trotta, Massimo Imazio, Emanuele Bizzi, Alessandro Andreis, Antonella Insalaco, JoAnn Clair, Allan L Klein, Enrico Tombetti, Antonio Brucato, John F Paolini

Zitieren

APA

Trotta, L., Imazio, M., Bizzi, E., Pancrazi, M., Andreis, A., Insalaco, A., Wang, S., Clair, J., Klein, A. L., Tombetti, E., Brucato, A., Paolini, J. F., & RHAPSODY Investigators (2026). Multiyear Recurrent Pericarditis Disease Duration: Clinical Outcomes After Cessation of Long‐Term Interleukin‐1 Pathway Inhibition Provide Insights for Chronic Management. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.044021

Vancouver

Trotta L, Imazio M, Bizzi E, Pancrazi M, Andreis A, Insalaco A, et al. Multiyear Recurrent Pericarditis Disease Duration: Clinical Outcomes After Cessation of Long‐Term Interleukin‐1 Pathway Inhibition Provide Insights for Chronic Management. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.044021

BibTeX
@article{Trotta2026,
  author = {Trotta, Lucia and Imazio, Massimo and Bizzi, Emanuele and Pancrazi, Massimo and Andreis, Alessandro and Insalaco, Antonella and Wang, Sheldon and Clair, JoAnn and Klein, Allan L and Tombetti, Enrico and Brucato, Antonio and Paolini, John F and RHAPSODY Investigators, RHAPSODY Investigators},
  title = {Multiyear Recurrent Pericarditis Disease Duration: Clinical Outcomes After Cessation of Long‐Term Interleukin‐1 Pathway Inhibition Provide Insights for Chronic Management},
  journal = {Journal of the American Heart Association},
  year = {2026},
  doi = {10.1161/jaha.125.044021}
}
Kostenlos starten →